Aehr Test Systems' lead hyperscale customer is expanding production with about $6M of follow-on Sonoma orders for a second-generation AI processor. These are production-capacity orders, not evaluations, and the customer expects the second processor eventually to exceed the volumes of the first, already in high-volume production. Teradyne's new burn-in on Titan HP overlaps only with package-level Sonoma work, not FOX-XP wafer-level burn-in that screens dies before costly CoWoS packaging. x.com 

Aehr Test Systems is growing fast across several verticals, with its lead AI processor customer placing another $22M follow-on order for wafer-level burn-in systems. The tiny company is expanding into memory and silicon photonics as well, and at about $1.1B market cap it looks extremely promising, resembling an early Teradyne. x.com 

Aehr remains a concentrated, expensive way to own wafer-level photonics burn-in: its 10-K says silicon-photonics customers primarily drove that revenue growth, and FY2027 guidance of $130m-$150m could nearly triple FY2026 sales, yet shares value it at about 20x the guide. Teradyne's acquired photonic-chip test business is not material to its much larger sales; Aehr's top five customers provided 70% of FY2026 revenue, so orders matter more than the headline CPO opportunity. x.com 

Aehr's AI burn-in growth case is intact, but confidence in its competitive edge may need to come down as Teradyne moves into high-power burn-in. Teradyne's Titan HP, already in production, combines system-level test and burn-in and could absorb spending on dedicated tools, pressuring Sonoma orders and pricing. Aehr still won about $6M of follow-on Sonoma orders for a hyperscaler's second AI chip, with no sign FOX-XP is replaced. If the market expands enough, revenue can grow as share falls. … Show more

Aehr Test Systems stands to benefit as testing takes a larger share of expanding semiconductor capex. Teradyne CEO Greg Smith says test's share of semiconductor capex rose from 6.4% in 2025 to 8.1% in the first eight months of 2026, with conditions favorable for prolonged ATE growth. Data-center reliability is pushing testing upstream from systems toward packages and wafers, where Aehr dominates wafer-level burn-in. Aehr lacks a dedicated CPU segment. x.com 

Aehr Test Systems' valuation looks ahead of its fundamentals after a strong turnaround quarter. Q4 FY2026 revenue rose 33% to $18.8 million with a return to GAAP profit, bookings hit a record $60.7 million and effective backlog topped $100.6 million. FY2027 guidance of $130-150 million implies 160-200% growth, so the post-earnings run prices in high expectations that depend on shipping FOX-XP systems on schedule without margin erosion. TRT is preferred for now. x.com  x.com 

Aehr Test Systems stands to benefit from Broadcom's custom AI chip ramp because these 600W–2kW multi-die packages need burn-in testing. Broadcom said XPU shipments rose 3.5x and laid out $115B of AI revenue in FY27 and $230B in FY28 with supply secured, backed by multi-gigawatt Google, Anthropic, OpenAI and Meta deployments. Aehr won a record $41M package-level burn-in order from its lead hyperscale customer for a custom AI ASIC, with a next-gen device moving to production later this year. x.com 

Aehr Test Systems' AI wafer-level burn-in business is scaling, with a $22M follow-on order from its lead AI processor customer to expand capacity for high-volume production. That customer is already planning more capacity, and Aehr is expanding talks with other hyperscalers. The stock reached fresh all-time highs, and its recent strength looks like institutional accumulation. x.com  x.com  x.com 

Aehr Test Systems is a case of narrative running ahead of the numbers. The bull case is reasonable: a young company with a strong position in silicon carbide burn-in, genuine hyperscaler interest in AI chip burn-in and room to expand into memory and logic. But the latest quarter showed revenue down 43% year over year, with no meaningful order conversion from the AI opportunities yet. Until revenue improves and orders come through more clearly, the story stays ahead of the fundamentals. x.com 

FormFactor and Aehr Test Systems are favored because testing is the one non-optional part of the AI buildout. A single bad die ruins the whole package, so pricier chips mean more testing. FormFactor's probe cards touch every wafer; Q2 set records above a $1B run rate with gross margin over 50%, HBM4 is two-thirds of DRAM revenue and a new GPU program ships this half. Aehr guides fiscal 2027 revenue up 160-200% to $130-150M on a record backlog, plus a $22M AI follow-on order. x.com